Evaluation of human tumor cell lines growth inhibition by Leccinum vulpinum Watling and Suillus granulatus (L.) Roussel
Conference Paper
Overview
Overview
abstract
FCT (Portugal) and COMPETE/QREN/EU for financial support through
PTDC/AGR/ALI/11 0062/2009 research project and PEst-OE/AGR/UI0690/2011 CIMO strategic
project. R.C.C. also thanks to POPH and FSE for the SFRH/BPD/68344/2010 grant.
Mushrooms comprise a vast and not yet totally explored source of powerful new pharmaceutical
products. In particular, and most importantly for modern medicine, they represent an unlimited
source of compounds which are modulators of tumour cell growth [1]. In the present work, the
anti-proliferative properties of two methanolic extracts of wild mushroom species from the
Northeast of Portugal (Leccinum vulpinum Watling and SuilIus granulatus (L.) Roussel) were
evaluated for the first time, allowing the comparison between these two species. These properties
were measured by sulforhodamine 8 (SRB) assay according to the procedure adopted in the
NCI's in vitro anticancer drug screening, observing their growth inhibitory activity. MCF-7 (breast
carcinoma), NCI-H460 (non-small lung carcinoma), HCT-15 (colon carcinoma) and HeLa (cervical
carcinoma) human cells lines were used. The concentration that inhibited growth in 50% is
expressed in Gl50. Both species were able to inhibit the proliferation of all the tested cell lines.
Nevertheless, the most susceptible cell line was HCT-15: Gl50 values 71.31±5.26 μg/ml for S.
Ganulatus and 77.61±2.22 μg/ml for L. vulpinum. Up to 400 μg/ml, the samples did not show
toxicity for non-tumor porcine liver primary cells. This study contributes for the valorisation of the
mentioned mushroom species due to their anti-proliferative properties against human tumor cell
lines.
